Doxycycline versus Prednisolone for the initial Treatment of bullous Pemphigoids: a pragmatic prospective randomized Study (2017) Schmidt E, Benoit S, Ehrchen J, Glaeser R, Guenther C, Steinbrink K, Sticherling M, et al. Conference contribution Activation of human C-Fibers by Lysophosphatidic Acid (2017) Düll M, Stengel M, Wurm L, Ries V, Kremer A, Namer B Conference contribution Old Age, nodular Melanoma, Tumor Thickness and Ulceration are Risk Factors for regional and systemic Metastases in Melanoma Patients after negative Sentinel Node Biopsy (2017) Erdmann M, Dominik S, Göhl J, Grützmann R, Schuler G, Schellerer V Conference contribution Fumaric Acid Esters and TNF alpha Inhibitors - Do they affect the Fertility of male Patients with Psoriasis? (2017) Heppt F, Colsmann A, Maronna A, Uslu U, Heppt M, Kiesewetter F, Sticherling M Conference contribution Fumaric Acid Esters: Patient Characteristics and Duration of Therapy from the PsoBest German Psoriasis Registry (2017) Augustin M, Reich K, Spehr C, Rustenbach SJ, Mrowietz U, Radtke MA, Wilsman-Theis D, et al. Conference contribution Hydradenitis suppurativa - new exploration on the famous Disease (2017) Oetterich K, Heppt F, Sticherling M Conference contribution Fear of progression in patients with low-risk malignant melanoma (2017) Wagner T, Augustin M, Blome C, Forschner A, Garbe C, Gutzmer R, Hauschild A, et al. Conference contribution Secukinumab Treatment of moderate to severe Plaque Psoriasis in the clinical Routine Care: Baseline Data from the PROSPECT Study on Psoriasis Pre-treatment (2017) Von Kiedrowski R, Korber A, Kraehn-Senftleben G, Sticherling M, Lange L, Bachhuber T, Kasparek TR, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without previous Systemic Therapy for Improvement of Skin Symptoms: PASI and IGA mod. 2011-Results of the PRIME Study (2017) Reich K, Mrowietz U, Augustin M, Thaci D, Kneidl J, Hentschke C, Simang M, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without prior System Therapy with respect to the Improvement of quality of life: DLQI and SF-36 Results of the PRIME Study (2017) Augustin M, Thaci D, Reich K, Mrowietz U, Kneidl J, Hentschke C, Simang M, et al. Conference contribution